Trial
NCT01549964
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Glycemic Control
Intervention
Fasiglifam (TAK-875)
Why stopped
Due to concerns about potential liver safety (See Detailed Description)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-02